HIV - GHealth News

Feb182022 by GHealth NewsNo Comments

Woman cured of HIV after stem cell transplant

Students of Yangzhou University in East China's Jiangsu Province, put red ribbon on their hands as an appeal to eliminate social discrimination against HIV patients on World AIDs Day. Photo: cnsphoto GHealth News - A patient with leukaemia in the United States has become the first woman and the third person to date to be cured of HIV after receiving a stem cell transplant, researchers say. The case, presented on Tuesday at the Conference on Retroviruses and Opportunisitic Infections in the US city of Denver, was the first involving umbilical cord blood to treat acute myeloid leukaemia, which starts in blood-forming cells in the bone marrow. Since receiving the cord blood, the middle-aged woman of mixed race has been in remission and free of HIV for 14 months, without the need for ...

COVID vaccines developed quickly — is a vaccine for HIV next?

HIV

By: Charli Shield It is a search that has so far eluded scientists for 40 years: Finding a safe and effective vaccine to protect people from HIV. Not a single HIV vaccine has made it beyond Phase III clinical testing in 37 years of research. In comparison to COVID-19, that timeline seems baffling. Over the last 18 months, more than 32 COVID vaccines have made it to Phase III clinical trials, eight have so far been approved and manufactured, and another 90 are in the Phase I and II pipeline. "When there's the political will, there is funding and resources," said Hendrik Streeck, virologist and director of the German Center of HIV &...

First long-acting HIV treatment approved in Europe

HIV

By: Hannah Balfour The European Commission approval of the long-acting injectable HIV treatment could transform the lives of people living with the disease. ViiV Healthcare has been given marketing authorisation (MA) for the first complete long-acting injectable HIV treatment in Europe. The authorisation means that, for the first time, people living with HIV in Europe have the option of a long-acting injectable treatment that removes the need to take daily oral tablets. The MA is for Vocabria (cabotegravir injection and tablets) in combination with Janssen Pharmaceutical Companies of Johnson & Johnson’s Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets) for the treatment of HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral re...